Taken together, our data suggest that the levels of BRD2 or BRD4 may represent a marker of sensitivity to BET inhibitors, and that a BET inhibitor can be effectively combined with IR to inhibit PC cell proliferation. The gene discussed is BRD2; the disease is pachyonychia congenita.